BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued

MT Newswires Live11-04

BioCryst Pharmaceuticals (BCRX) reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.06.

Revenue for the quarter ended Sept. 30 was $117.1 million, up from $86.7 million a year earlier.

Analysts surveyed by Capital IQ expected $114 million.

Cash, cash equivalents, restricted cash and investments as of Sept. 30 came in at $351.7 million, compared with $399.2 million a year earlier.

For 2024, the company said it expects revenue of $443 million to $448 million.

Analysts surveyed by Capital IQ expect $436.3 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480300666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480300666","market":"sg","top_or_hot":-1,"title":"BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued","media":"MT Newswires Live","content":"<html><body><p> BioCryst Pharmaceuticals (BCRX) reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.</p><p>Analysts polled by Capital IQ expected a loss of $0.06.</p><p>Revenue for the quarter ended Sept. 30 was $117.1 million, up from $86.7 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $114 million.</p><p>Cash, cash equivalents, restricted cash and investments as of Sept. 30 came in at $351.7 million, compared with $399.2 million a year earlier.</p><p>For 2024, the company said it expects revenue of $443 million to $448 million.</p><p>Analysts surveyed by Capital IQ expect $436.3 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst Pharmaceuticals (BCRX) reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by Capital IQ expected a loss of $0.06.Revenue for ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2480300666","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480300666","pubTimestamp":1730725319,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioCryst Pharmaceuticals  reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by Capital IQ expected a loss of $0.06.Revenue for the quarter ended Sept. 30 was $117.1 million, up from $86.7 million a year earlier.Analysts surveyed by Capital IQ expected $114 million.Cash, cash equivalents, restricted cash and investments as of Sept. 30 came in at $351.7 million, compared with $399.2 million a year earlier.For 2024, the company said it expects revenue of $443 million to $448 million.Analysts surveyed by Capital IQ expect $436.3 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"BioCryst Pharmaceuticals第三季度亏损收窄，营收上升；发布2024年销售指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":0.9},"content_text":"BioCryst Pharmaceuticals (BCRX) reported a Q3 loss Monday of $0.07 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by Capital IQ expected a loss of $0.06.Revenue for the quarter ended Sept. 30 was $117.1 million, up from $86.7 million a year earlier.Analysts surveyed by Capital IQ expected $114 million.Cash, cash equivalents, restricted cash and investments as of Sept. 30 came in at $351.7 million, compared with $399.2 million a year earlier.For 2024, the company said it expects revenue of $443 million to $448 million.Analysts surveyed by Capital IQ expect $436.3 million.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480300666"}